Vientiane, Laos - April 28, 2023 - Big Bear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative therapies for cancer, announced today that it has received approval from the Ministry of Health of Laos for six anti-cancer targeted drugs.
The approved drugs are:
The approval of these drugs marks a significant milestone for Big Bear Pharma and its mission to bring innovative and effective treatments to patients with cancer in Laos and beyond. The company plans to launch the drugs in the local market in the coming months and to expand its presence in the Southeast Asian region.
“We are thrilled to receive the approval of our six anti-cancer targeted drugs in Laos, which demonstrates our commitment to delivering cutting-edge therapies to patients in need,” said Nipaporn Khunkaw, CEO of Big Bear Pharma. “We are grateful to the Ministry of Health of Laos for their support and collaboration throughout the regulatory process. We look forward to working with them and other stakeholders to ensure the accessibility and affordability of our drugs for the people of Laos.”
About Big Bear Pharma
Big Bear Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer. The company has a diverse pipeline of anti-cancer targeted drugs that address various molecular pathways and mechanisms of action. Big Bear Pharma aims to improve the lives of patients with cancer by providing them with more options, better outcomes and lower costs.
To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.